FDA Approves Blinatumomab for 72- and 96-Hour Infusion Durations

On December 17, the US Food and Drug Administration approved blinatumomab for 72- and 96-hour infusion durations to offer more flexibility for physicians and their patients.

For more information visit the BLINCYTO website.

Posted on 12/23/2024